{"success":true,"data":{"pressRelease":{"id":"7240","rtpr_id":"nGNXcdzJHS","ticker":"GOSS","exchange":"NASDAQ","all_tickers":["GOSS","MEDP","NUAI"],"title":"DEADLINE ALERT for GOSS, NUAI, and MEDP: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders","author":"Globe Newswire","published_at":"2026-04-23T16:04:00.120Z","article_body":"LOS ANGELES, April 23, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R.\nCruz\n(https://www.globenewswire.com/Tracker?data=Emq7jCxvDHhbPgyI7XmRMghVeiKIHK3XPwQzjBmlNtlOU8NlRmthisfteRLnbCa1d-Ejfoowno4t1MVHy4DooN0ukq-b7DEAeg1bfAwowu6SqWWmbst5Tg53EGXk6pb6)\nreminds investors that class action lawsuits have been filed on behalf of\nshareholders of the following publicly-traded companies. Investors have until\nthe deadlines listed below to file a lead plaintiff motion.\n\nInvestors suffering losses on their investments are encouraged to contact The\nLaw Offices of Frank R. Cruz to discuss their legal rights in these class\nactions at 310-914-5007 or by email to fcruz@frankcruzlaw.com.\n\nGossamer Bio, Inc. (NASDAQ: GOSS\n(https://www.globenewswire.com/Tracker?data=SuFGmrwhgmG9TQV03qQzHUY6ZvQUMYrc8rgXtglhRCILfMfPOJmx0_m6ppdBkaU1dBQi4Zdv_VNv54vr6ZUyKu-YWyIUydFbjgL_DOkNHLg=))\nClass Period: June 16, 2025 – February 20, 2026\nLead Plaintiff Deadline: June 1, 2026\n\nThe complaint filed in this class action alleges that throughout the Class\nPeriod, Defendants made materially false and/or misleading statements, as well\nas failed to disclose material adverse facts about the Company’s business,\noperations, and prospects. Specifically, Defendants failed to disclose to\ninvestors that: (1) patients at the Latin American sites were largely\nheavily-treated and lower risk and, ultimately, performed particularly well on\nthe placebo, thus, Gossamer’s Phase 3 PROSERA study failed to meet the\nprimary endpoint of improved six-minute walk distance at week 24; and (2) as a\nresult, Defendants’ positive statements about the Company’s business,\noperations, and prospects were materially misleading and/or lacked a\nreasonable basis at all relevant times.\n\nIf you are a Gossamer shareholder who suffered a loss, click here\n(https://www.globenewswire.com/Tracker?data=UFDd-khzpfWBTCFfE_07gguk2BArq7FXmoPDkUq1ZpnQSSKRkQhGWQc-itIrapDCyHiW1_ISugLfc5PAC1bgEvU5dwEXop0h-ERJ5E4lllP4ytPQF-1mK4Ms0R1RDWYe)\nto participate.\n\nNew Era Energy & Digital, Inc. (NASDAQ: NUAI\n(https://www.globenewswire.com/Tracker?data=73LvMn3uLeErF8b2j3kSyy54wawHXoiI66QfG2WyylMSxf27H-391KdwHKTBCspe3-YHGF4V86POAxQiO35FIhc2v3UYAWYB0-T_a0mlqE0=))\nClass Period: November 6, 2024 – December 29, 2025\nLead Plaintiff Deadline: June 1, 2026\n\nThe complaint filed in this class action alleges that throughout the Class\nPeriod, Defendants made materially false and/or misleading statements, as well\nas failed to disclose material adverse facts about the Company’s business,\noperations, and prospects. Specifically, Defendants failed to disclose to\ninvestors: (1) the Company overstated its progress in its permitting and\nregulatory filings for its flagship Texas Critical Data Centers project; (2)\nthe Company was involved in a fraudulent scheme “to pocket revenues from\nhundreds of oil and gas wells in New Mexico” by transferring wells among\nrelated entities and then placing liability-bearing companies into bankruptcy\nto avoid plugging and remediation costs; (3) that, as a result, the\nCompany’s financial results were false and/or misleading; and (4) that, as a\nresult of the foregoing, Defendants’ positive statements about the\nCompany’s business, operations, and prospects were materially misleading\nand/or lacked a reasonable basis.\n\nIf you are a New Era shareholder who suffered a loss, click here\n(https://www.globenewswire.com/Tracker?data=UFDd-khzpfWBTCFfE_07gmZkA8ZubE3lXUcJVLbyON-1zeenBR_u-_jCv5qCA6IpoLXEyP1X3jYyzRluI9Q6dlfcuGo1IhygYF7OiXlpVazZImt-Az7KSUMtpntzQRhs)\nto participate.\n\nMedpace Holdings, Inc. (NASDAQ: MEDP\n(https://www.globenewswire.com/Tracker?data=RxwH3RTCUtzSP_cH4VLO1RYmDty7G_PlhAnS-0T7Drk0LlMSSsmbacK7zc0Y8qN0dIwfICVXPU9H4PwhW70Ly4RmagomJJ94pfa410BQt4k=))\nClass Period: April 22, 2025 – February 9, 2026\nLead Plaintiff Deadline: June 5, 2026\n\nThe complaint filed in this class action alleges that throughout the Class\nPeriod, Defendants made materially false and/or misleading statements, as well\nas failed to disclose material adverse facts about the Company’s business,\noperations, and prospects. Specifically, Defendants: (1) consistently oversold\nthe Company’s projected book-to-bill ratio for fourth quarter 2025; (2) knew\nor recklessly disregarded the impact that cancellations have on the\nCompany’s book-to-bill ratio; (3) frequently claimed that the projection of\na 1.15 book-to-bill ratio for fourth quarter 2025 was reasonable and\nachievable and that cancellations were not a sign of a weak business\nenvironment; (4) reassured investors that the Company was not concerned about\nthe lack of diversity in its pre-backlog; (5) stated that, despite the uptick\nin metabolic growth, the Company’s upside was broad-based and not isolated\nto any handful of studies; and (6) as a result, Defendants’ positive\nstatements about the Company’s business, operations, and prospects were\nmaterially misleading and/or lacked a reasonable basis at all relevant times.\n\nIf you are a Medpace shareholder who suffered a loss, click here\n(https://www.globenewswire.com/Tracker?data=UFDd-khzpfWBTCFfE_07giObW15mU2Fpv1t-4WFmVblEjwDRj9bDEkOopHanrItSzu8YzD0MQV8ssyYIi0tZoXr3yXuCpwiIEHGx5MAmb5taReRlbWHeBLTm60vidFX6)\nto participate.\n\nFollow us for updates on Twitter: twitter.com/FRC_LAW\n(https://www.globenewswire.com/Tracker?data=3NQYhx93Yy9NZ9DkED_4koEGdFZ04v-0LUFTu3WOxRCcg5pKUsMQEII42I2bjxHdNxzKw9YGdHqN_2wuk-e5EZHkaINkSZ5twE0GaUpK78U=).\n\nTo be a member of these class actions, you need not take any action at this\ntime; you may retain counsel of your choice or take no action and remain an\nabsent member of the class action. If you wish to learn more about these\nclass actions, or if you have any questions concerning this announcement or\nyour rights or interests with respect to these matters, please contact Frank\nR. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite\n1100, Los Angeles, California 90067 at 310-914-5007, by email to\ninfo@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you\ninquire by email please include your mailing address, telephone number, and\nnumber of shares purchased.\n\nThis press release may be considered Attorney Advertising in some\njurisdictions under the applicable law and ethical rules.\n\nContacts\n\nThe Law Offices of Frank R. Cruz, Los Angeles\nFrank R. Cruz, 310-914-5007\nfcruz@frankcruzlaw.com\nwww.frankcruzlaw.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/778ea178-25d1-48a3-9141-a162814899d4)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXcdzJHS","title":"DEADLINE ALERT for GOSS, NUAI, and MEDP: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders","author":"Globe Newswire","ticker":"GOSS","created":"2026-04-23T16:04:00.120Z","tickers":["GOSS","MEDP","NUAI"],"exchange":"NASDAQ","article_body":"LOS ANGELES, April 23, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R.\nCruz\n(https://www.globenewswire.com/Tracker?data=Emq7jCxvDHhbPgyI7XmRMghVeiKIHK3XPwQzjBmlNtlOU8NlRmthisfteRLnbCa1d-Ejfoowno4t1MVHy4DooN0ukq-b7DEAeg1bfAwowu6SqWWmbst5Tg53EGXk6pb6)\nreminds investors that class action lawsuits have been filed on behalf of\nshareholders of the following publicly-traded companies. Investors have until\nthe deadlines listed below to file a lead plaintiff motion.\n\nInvestors suffering losses on their investments are encouraged to contact The\nLaw Offices of Frank R. Cruz to discuss their legal rights in these class\nactions at 310-914-5007 or by email to fcruz@frankcruzlaw.com.\n\nGossamer Bio, Inc. (NASDAQ: GOSS\n(https://www.globenewswire.com/Tracker?data=SuFGmrwhgmG9TQV03qQzHUY6ZvQUMYrc8rgXtglhRCILfMfPOJmx0_m6ppdBkaU1dBQi4Zdv_VNv54vr6ZUyKu-YWyIUydFbjgL_DOkNHLg=))\nClass Period: June 16, 2025 – February 20, 2026\nLead Plaintiff Deadline: June 1, 2026\n\nThe complaint filed in this class action alleges that throughout the Class\nPeriod, Defendants made materially false and/or misleading statements, as well\nas failed to disclose material adverse facts about the Company’s business,\noperations, and prospects. Specifically, Defendants failed to disclose to\ninvestors that: (1) patients at the Latin American sites were largely\nheavily-treated and lower risk and, ultimately, performed particularly well on\nthe placebo, thus, Gossamer’s Phase 3 PROSERA study failed to meet the\nprimary endpoint of improved six-minute walk distance at week 24; and (2) as a\nresult, Defendants’ positive statements about the Company’s business,\noperations, and prospects were materially misleading and/or lacked a\nreasonable basis at all relevant times.\n\nIf you are a Gossamer shareholder who suffered a loss, click here\n(https://www.globenewswire.com/Tracker?data=UFDd-khzpfWBTCFfE_07gguk2BArq7FXmoPDkUq1ZpnQSSKRkQhGWQc-itIrapDCyHiW1_ISugLfc5PAC1bgEvU5dwEXop0h-ERJ5E4lllP4ytPQF-1mK4Ms0R1RDWYe)\nto participate.\n\nNew Era Energy & Digital, Inc. (NASDAQ: NUAI\n(https://www.globenewswire.com/Tracker?data=73LvMn3uLeErF8b2j3kSyy54wawHXoiI66QfG2WyylMSxf27H-391KdwHKTBCspe3-YHGF4V86POAxQiO35FIhc2v3UYAWYB0-T_a0mlqE0=))\nClass Period: November 6, 2024 – December 29, 2025\nLead Plaintiff Deadline: June 1, 2026\n\nThe complaint filed in this class action alleges that throughout the Class\nPeriod, Defendants made materially false and/or misleading statements, as well\nas failed to disclose material adverse facts about the Company’s business,\noperations, and prospects. Specifically, Defendants failed to disclose to\ninvestors: (1) the Company overstated its progress in its permitting and\nregulatory filings for its flagship Texas Critical Data Centers project; (2)\nthe Company was involved in a fraudulent scheme “to pocket revenues from\nhundreds of oil and gas wells in New Mexico” by transferring wells among\nrelated entities and then placing liability-bearing companies into bankruptcy\nto avoid plugging and remediation costs; (3) that, as a result, the\nCompany’s financial results were false and/or misleading; and (4) that, as a\nresult of the foregoing, Defendants’ positive statements about the\nCompany’s business, operations, and prospects were materially misleading\nand/or lacked a reasonable basis.\n\nIf you are a New Era shareholder who suffered a loss, click here\n(https://www.globenewswire.com/Tracker?data=UFDd-khzpfWBTCFfE_07gmZkA8ZubE3lXUcJVLbyON-1zeenBR_u-_jCv5qCA6IpoLXEyP1X3jYyzRluI9Q6dlfcuGo1IhygYF7OiXlpVazZImt-Az7KSUMtpntzQRhs)\nto participate.\n\nMedpace Holdings, Inc. (NASDAQ: MEDP\n(https://www.globenewswire.com/Tracker?data=RxwH3RTCUtzSP_cH4VLO1RYmDty7G_PlhAnS-0T7Drk0LlMSSsmbacK7zc0Y8qN0dIwfICVXPU9H4PwhW70Ly4RmagomJJ94pfa410BQt4k=))\nClass Period: April 22, 2025 – February 9, 2026\nLead Plaintiff Deadline: June 5, 2026\n\nThe complaint filed in this class action alleges that throughout the Class\nPeriod, Defendants made materially false and/or misleading statements, as well\nas failed to disclose material adverse facts about the Company’s business,\noperations, and prospects. Specifically, Defendants: (1) consistently oversold\nthe Company’s projected book-to-bill ratio for fourth quarter 2025; (2) knew\nor recklessly disregarded the impact that cancellations have on the\nCompany’s book-to-bill ratio; (3) frequently claimed that the projection of\na 1.15 book-to-bill ratio for fourth quarter 2025 was reasonable and\nachievable and that cancellations were not a sign of a weak business\nenvironment; (4) reassured investors that the Company was not concerned about\nthe lack of diversity in its pre-backlog; (5) stated that, despite the uptick\nin metabolic growth, the Company’s upside was broad-based and not isolated\nto any handful of studies; and (6) as a result, Defendants’ positive\nstatements about the Company’s business, operations, and prospects were\nmaterially misleading and/or lacked a reasonable basis at all relevant times.\n\nIf you are a Medpace shareholder who suffered a loss, click here\n(https://www.globenewswire.com/Tracker?data=UFDd-khzpfWBTCFfE_07giObW15mU2Fpv1t-4WFmVblEjwDRj9bDEkOopHanrItSzu8YzD0MQV8ssyYIi0tZoXr3yXuCpwiIEHGx5MAmb5taReRlbWHeBLTm60vidFX6)\nto participate.\n\nFollow us for updates on Twitter: twitter.com/FRC_LAW\n(https://www.globenewswire.com/Tracker?data=3NQYhx93Yy9NZ9DkED_4koEGdFZ04v-0LUFTu3WOxRCcg5pKUsMQEII42I2bjxHdNxzKw9YGdHqN_2wuk-e5EZHkaINkSZ5twE0GaUpK78U=).\n\nTo be a member of these class actions, you need not take any action at this\ntime; you may retain counsel of your choice or take no action and remain an\nabsent member of the class action. If you wish to learn more about these\nclass actions, or if you have any questions concerning this announcement or\nyour rights or interests with respect to these matters, please contact Frank\nR. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite\n1100, Los Angeles, California 90067 at 310-914-5007, by email to\ninfo@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you\ninquire by email please include your mailing address, telephone number, and\nnumber of shares purchased.\n\nThis press release may be considered Attorney Advertising in some\njurisdictions under the applicable law and ethical rules.\n\nContacts\n\nThe Law Offices of Frank R. Cruz, Los Angeles\nFrank R. Cruz, 310-914-5007\nfcruz@frankcruzlaw.com\nwww.frankcruzlaw.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/778ea178-25d1-48a3-9141-a162814899d4)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-04-23T16:04:00.173368136Z","server_sent_at_ms":1776960240173},"received_at":"2026-04-23T16:04:00.235Z","source_url":null},"analysis":{"id":"5426","press_release_id":"7240","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["Class action lawsuit alleges securities fraud","Allegations include failure to disclose patient selection flaws in Phase 3 study"],"eventType":"legal_litigation","narrative":"The Law Offices of Frank R. Cruz announced a class action lawsuit against Gossamer Bio on behalf of shareholders who suffered losses.\n\nThe complaint alleges the company made materially false statements regarding its Phase 3 PROSERA study, specifically failing to disclose that patients at Latin American sites were lower risk and heavily treated, which contributed to the study failing its primary endpoint.\n\nInvestors have until June 1, 2026, to file a lead plaintiff motion to participate in the class action.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"Securities fraud class action filed against Gossamer Bio regarding PROSERA trial disclosures."},"namedEntities":{"people":[{"name":"Frank R. Cruz","role":"Attorney"}],"products":["PROSERA study"],"companies":[{"name":"Gossamer Bio, Inc.","ticker":"GOSS"},{"name":"New Era Energy & Digital, Inc.","ticker":"NUAI"},{"name":"Medpace Holdings, Inc.","ticker":"MEDP"},{"name":"The Law Offices of Frank R. Cruz","relationship":"counsel"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"The filing of a securities class action alleging fraud related to a recent clinical trial failure adds legal and financial risk, though the primary market-moving event was likely the clinical data itself."},"tickerRelevance":{"others":[{"ticker":"NUAI","relevance":"mentioned"},{"ticker":"MEDP","relevance":"mentioned"}],"primary":"GOSS"},"eventTypeSecondary":[]},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"bearish","material_impact_score":3,"narrative":"The Law Offices of Frank R. Cruz announced a class action lawsuit against Gossamer Bio on behalf of shareholders who suffered losses.\n\nThe complaint alleges the company made materially false statements regarding its Phase 3 PROSERA study, specifically failing to disclose that patients at Latin American sites were lower risk and heavily treated, which contributed to the study failing its primary endpoint.\n\nInvestors have until June 1, 2026, to file a lead plaintiff motion to participate in the class action.","key_figures":null,"named_entities":{"people":[{"name":"Frank R. Cruz","role":"Attorney"}],"products":["PROSERA study"],"companies":[{"name":"Gossamer Bio, Inc.","ticker":"GOSS"},{"name":"New Era Energy & Digital, Inc.","ticker":"NUAI"},{"name":"Medpace Holdings, Inc.","ticker":"MEDP"},{"name":"The Law Offices of Frank R. Cruz","relationship":"counsel"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:2f2748f0fcc8c4f2","schema_hash":"sha256:ad96b863d7123008","created_at":"2026-04-23T22:14:48.546Z","global_importance":3,"audience_relevance":3,"importance_components":{"method":"backfill-heuristic","signals":{"bodyLong":false,"headlineTier1":false,"tickerCovered":false,"hadSignificance":false},"version":1,"computedAt":"2026-04-27T11:52:55.062Z"}},"durationMs":47280,"modelName":"glm-4.7"}}